Keyword: Semma Therapeutics
Carmen Bozic, M.D., Vertex's new head of global medicines development and medical affairs, will take over the CMO post April 1.
Vertex Pharmaceuticals is jumping into diabetes with a $950 million acquisition of Semma Therapeutics and its stem cell-based diabetes treatments.
The week’s biotech news included one stem-cell-derived treatment for diabetes and another for regrowing hair.
Semma and Harvard scientists are reporting they've figured out how to regenerate high quantities of insulin-producing beta cells.
Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.
Semma Therapeutics named Bastiano Sanna, formerly of Novartis’ cell and gene therapy unit and Magenta Therapeutics, as its president and CEO.
Scientists in the U.S. and Japan devised a new tissue engineering method to tackle blood supply problems in pancreatic cell transplantation.
Researchers confirmed that the pancreas contains stem cells that can become insulin-producing cells.
The round positions Semma to start learning whether its insulin-producing cells can control blood sugar levels in Type 1 diabetics.